FangM, WangD, CoreshJ, SelvinE. Trends in diabetes treatment and control in U.S. adults, 1999–2018. N Engl J Med, 2021; 384: 2219–2228.
2.
LalRA, MaahsDM, DosiouC, AyeT, BasinaM. The guided transfer of care improves adult clinic show rate. Endocr Pract, 2020; 26: 508–513.
3.
RizzaRA, VigerskyRA, RodbardHW, et al.A model to determine workforce needs for endocrinologists in the United States until 2020. Diabetes Care, 2003; 26: 1545–1552.
4.
StewartAF. The United States endocrinology workforce: A supply-demand mismatch. J Clin Endocrinol Metab, 2008; 93: 1164–1166.
5.
VigerskyRA, FishL, HoganP, et al.The clinical endocrinology workforce: Current status and future projections of supply and demand. J Clin Endocrinol Metab, 2014; 99: 3112–3121.
6.
LalRA, CuttrissN, HallerMJ, et al.Primary care providers in California and Florida report low confidence in providing type 1 diabetes care. Clin Diabetes, 2020; 38: 159–165.
7.
BainSC, KlufasMA, HoA, MatthewsDR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab, 2019; 21: 454–466.
8.
van BallegooieE, HooymansJM, TimmermanZ, et al.Rapid deterioration of diabetic retinopathy during treatment with continuous subcutaneous insulin infusion. Diabetes Care, 1984; 7: 236–242.
9.
KellyTM, SanbornGE, HaugPJ, EdwardsCQ. Effect of insulin infusion pump use on diabetic retinopathy. Arch Ophthalmol, 1984; 102: 1156–1159.
10.
JeyamA, ColhounH, McGurnaghanS, et al.Clinical impact of residual c-peptide secretion in type 1 diabetes on glycemia and microvascular complications. Diabetes Care, 2021; 44: 390–398.
11.
PickupJC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med, 2012; 366: 1616–1624.
12.
PickupJC. Is insulin pump therapy effective in type 1 diabetes?. Diabet Med, 2019; 36: 269–278.
13.
O'ReillyJE, JeyamA, CaparrottaTM, et al.Rising rates and widening socioeconomic disparities in diabetic ketoacidosis in type 1 diabetes in Scotland: A nationwide retrospective cohort observational study. Diabetes Care, 2021; 44: 2010–2017.
14.
KargesB, SchwandtA, HeidtmannB, et al.Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA, 2017; 318: 1358–1366.
15.
Fazeli FarsaniS, BrodoviczK, SoleymanlouN, MarquardJ, WissingerE, MaieseBA. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): A systematic literature review. BMJ Open, 2017; 7: e016587.
16.
BellKJ, SmartCE, SteilGM, Brand-MillerJC, KingB, WolpertHA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: Implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care, 2015; 38: 1008–1015.
17.
PatersonM, BellKJ, O'ConnellSM, SmartCE, ShafatA, KingB. The role of dietary protein and fat in glycaemic control in type 1 diabetes: Implications for intensive diabetes management. Curr Diab Rep, 2015; 15: 61.
18.
ElleriD, AllenJM, HarrisJ, et al.Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. Diabetologia, 2013; 56: 1108–1117.
19.
ReznikY, CohenO, AronsonR, et al.Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): A randomised open-label controlled trial. Lancet, 2014; 384(9950): 1265–1272.
20.
AronsonR, ReznikY, CongetI, et al.Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab, 2016; 18: 500–507.
21.
PickupJC, ReznikY, SuttonAJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: Individual patient data meta-analysis and meta-regression of randomized controled trials. Diabetes Care, 2017; 40: 715–722.
22.
CookCB, BeerKA, SeifertKM, BoyleME, MackeyPA, CastroJC. Transitioning insulin pump therapy from the outpatient to the inpatient setting: A review of 6 years' experience with 253 cases. J Diabetes Sci Technol, 2012; 6: 995–1002.
23.
BailonRM, PartlowBJ, Miller-CageV, et al.Continuous subcutaneous insulin infusion (insulin pump) therapy can be safely used in the hospital in select patients. Endocr Pract, 2009; 15: 24–29.
24.
FreckmannG, KameckeU, WaldenmaierD, HaugC, ZieglerR. Accuracy of bolus and basal rate delivery of different insulin pump systems. Diabetes Technol Ther, 2019; 21: 201–208.
25.
LaubnerK, SinglerE, StraetenerJ, SiegmundT, PäthG, SeufertJ. Comparative dose accuracy of durable and patch insulin pumps under laboratory conditions. Diabetes Technol Ther, 2019; 21: 371–378.
26.
GirardotS, JacquemierP, MousinF, RendekeuC, HardyS, RivelineJP. All insulin pumps are not equivalent: A bench test assessment for several basal rates. Diabetes Technol Ther, 2020; 22: 476–483.
